Information Provided By:
Fly News Breaks for February 9, 2016
LJPC
Feb 9, 2016 | 06:15 EDT
Cowen analyst Phil Nadeau initiated La Jolla with an Outperform rating and $40 price target on shares. The analyst said La Jolla's lead candidate, LJPC-501, an angiotensin II vasoconstrictor and a key regulator of blood pressure, will succeed in its Phase III trial in late 2016 and estimates that peak U.S. sales potential of over $1B.
News For LJPC From the Last 2 Days
There are no results for your query LJPC